Navigation Links
Transition Therapeutics Announces Fiscal 2007 Year End Financial Results
Date:9/12/2007

p> 2007 2006

$ $

-------------------------------------------------------------------------

REVENUES

Milestone revenue 552,650 -

Upfront and licensing fees 131,244 131,244

Management fees from ENI - 239,930

-------------------------------------------------------------------------

683,894 371,174

-------------------------------------------------------------------------

EXPENSES

Research and development 9,839,170 11,060,455

General and administrative 5,317,524 3,140,800

Amortization 6,823,259 9,563,274

Foreign exchange loss (gain) 6,875 (82,043)

Loss on disposal of capital assets and assets

held for sale 14,377 58,034

-------------------------------------------------------------------------

22,001,205 23,740,520

-------------------------------------------------------------------------

Loss before the following (21,317,311) (23,369,346)

Interest income, net 1,226,099 350,380

Equity loss in affiliate - (477,723)

Gain (losses) of company transferred under

contractual arrangement 400,000 (618,922)

-------------------------------------------------------------------------

Loss before income taxes (19,691,212) (24,115,611)

Future income taxes recovery
'/>"/>

SOURCE Transition Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19

Related medicine news :

1. Mans Transition from Foragers to Agriculturalist Led to Increase in Birth Rates
2. Rocky Transition to the Medicare Drug Program
3. Customized Post Operation Care Offers Patients a Smooth Transition to Patients into the Community
4. Mental Health - NHS Trust Commences Specialist Transition Service
5. Permanent Weight Loss Requires Transition to Healthy Eating
6. VBI Provides Potential Targets to Diabetes Therapeutics
7. CELL THERAPEUTICS PAYS Heavily to Resolve Dispute FOR ALLEGED ILLEGAL MARKETING OF CANCER DRUG
8. PM announces a new health care order for India
9. Ramdoss Announces Introduction of RCH-II
10. Britain Announces Third Transfusion Related Mad Cow Case
11. Gates Foundation Announces $287 Million In Grants Towards AIDS Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
Other Medicine News:Health News:UnitedLex Announces Strategic Alliance with Oval Ideas to Enable Superior Patent Analytics 2Health News:What's That Smell? Ask a Woman, Not a Man 2Health News:Acid Erosion In Children's Teeth Growing Concern Among Dentists 2Health News:Acid Erosion In Children's Teeth Growing Concern Among Dentists 3Health News:Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States 2Health News:Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States 3Health News:Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States 4Health News:Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States 5Health News:Aplenzin(TM), the Only Single Tablet Once-Daily Treatment for Depression at All Doses, Now Available in the United States 6Health News:Introducing solixir(TM)... The First All-Natural Sparkling Botanical Beverage to Hydrate Body and Soul 2Health News:Introducing solixir(TM)... The First All-Natural Sparkling Botanical Beverage to Hydrate Body and Soul 3
Breaking Medicine Technology:Pharmacy Technician Employment Increasing Up to 32% By 2016 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 2Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 3Final Data from Phase 2 Study Confirm High Response Rate of Micromet's Blinatumomab in Patients with Acute Lymphoblastic Leukemia 4ARKRAY, Inc. Announces Partnership With scil animal care company for the SPOTCHEM(TM) EZ Analyzer 2Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 1Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 2Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 3Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 4Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 5Escalon 28R 29 Subsidiary Sonomed Introduces New PacScan 28TM 29 Plus A Scan and Pachymeter 5667 6Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study 5663 1Biomoda Enters Final Stage of Patient Testing for Phase II Lung Cancer Clinical Study 5663 2NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 1NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 2NASCAR Camping World Truck Series Driver Aric Almirola Waves the Yellow Flag at Warning Signs of Skin Cancer 5659 3
Other Medicine Technology:CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 2CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 3CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 4CHMP Recommends Approval of New Indication for Enbrel(R) as Treatment for Severe Psoriasis in Paediatric Patients 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 2FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 3FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 4FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 5FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 6FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 7FDA Approves Promacta(R) (Eltrombopag), the First Oral Medication to Increase Platelet Production for People With Serious Blood Disorder 8